Table 3. Correlation among patients’ age, sex and KRAS mutational status.
| Samples | Age | Sex | KRAS mutation (AF) |
|---|---|---|---|
| 1 | 36 | F | p.G12D (1.5%) |
| 2 | 64 | M | p.G12C (1.3%) |
| 3 | 48 | M | p.G12C (0.6%) |
| 4 | 59 | F | p.G12D (1.3%) |
| 5 | 89 | M | p.G12D (7.2%) |
| 6 | 62 | M | p.G12C (5.6%) |
| 7 | 64 | M | p.G13S (0.2%) |
| 8 | 76 | F | p.G13D (0.3%) |
| 9 | 69 | M | p.G12S (6.4%) |
| 10 | 65 | M | p.G12C (3.3%) |
| 11 | 84 | M | p.G13S (0.2%) |
| 12 | 74 | F | p.G12C (24.0%) |
| 13 | 73 | F | p.G12C (0.9%) |
| 14 | 49 | M | p.G12S (1.4%) |
| 15 | 61 | F | p.G12C (4.6%) |
| 16 | 69 | M | p.G12C (46.8%) |
| 17 | 70 | M | p.G12S (7.1%) |
| 18 | 65 | F | p.G12V (24.0%) |
| 19 | 68 | M | p.G12D (0.9%) |
| 20 | 58 | M | p.G12C (3.9%) |
| 21 | 65 | F | p.G12C (2.5%) |
| 22 | 69 | M | p.G13D (0.4%) |
| 23 | 73 | M | p.G12C (2.9%) |
| 24 | 84 | M | p.G13S (0.6%) |
| 25 | 70 | M | p.G13S (0.7%) |
| 26 | 65 | M | p.G13D (4.2%) |
| 27 | 63 | M | p.G12C (4.7%) |
| 28 | 78 | M | p.G12D (2.0%) |
| 29 | 77 | M | p.G12A (0.7%) |
| 30 | 81 | F | p.G12V (1.0%) |
| 31 | 51 | F | p.G12C (3.1%) |
| 32 | 68 | M | p.G13D (0.7%) |
| 33 | 52 | F | p.G12V (4.6%) |
| 34 | 70 | M | p.Q61H (0.2%) |
| 35 | 77 | M | p.Q61H (4.7%) |
| 36 | 64 | F | p.A59V (0.2%) |
KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog; AF, allelic frequency; F, female; M, male.